MX2023007181A - Compuestos de union a tau. - Google Patents
Compuestos de union a tau.Info
- Publication number
- MX2023007181A MX2023007181A MX2023007181A MX2023007181A MX2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A MX 2023007181 A MX2023007181 A MX 2023007181A
- Authority
- MX
- Mexico
- Prior art keywords
- binding compounds
- tau binding
- tau
- tau antibodies
- diagnosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126024P | 2020-12-16 | 2020-12-16 | |
| PCT/US2021/063551 WO2022132923A1 (en) | 2020-12-16 | 2021-12-15 | Tau binding compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023007181A true MX2023007181A (es) | 2023-08-30 |
Family
ID=80112434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023007181A MX2023007181A (es) | 2020-12-16 | 2021-12-15 | Compuestos de union a tau. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059766A1 (enExample) |
| EP (1) | EP4263599A1 (enExample) |
| JP (1) | JP2023554382A (enExample) |
| KR (1) | KR20230157296A (enExample) |
| CN (1) | CN117043183A (enExample) |
| AU (1) | AU2021403010A1 (enExample) |
| CA (1) | CA3205586A1 (enExample) |
| IL (1) | IL303638A (enExample) |
| MX (1) | MX2023007181A (enExample) |
| TW (1) | TW202239765A (enExample) |
| WO (1) | WO2022132923A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| JP2025535203A (ja) | 2022-09-15 | 2025-10-23 | ボイジャー セラピューティクス インコーポレイテッド | タウ結合化合物 |
| CN121773336A (zh) * | 2023-07-20 | 2026-03-31 | 拉亚·蒙托柳加亚 | P-tau免疫测定 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2026102093A1 (en) | 2024-11-07 | 2026-05-15 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN121758610B (zh) * | 2026-03-03 | 2026-07-31 | 杭州星源华青生物科技有限公司 | Tau蛋白289磷酸化位点特异性结合蛋白、阿尔兹海默症诊断试剂盒及其制备方法与应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| AU690092B2 (en) | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ，インコーポレイティド | 人工抗体ポリペプチド |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| ES2645563T3 (es) | 2001-11-30 | 2017-12-05 | Amgen Fremont Inc. | Animales transgénicos que portan genes de cadena ligera de Ig humana |
| US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| PL2346994T3 (pl) | 2008-09-30 | 2022-04-19 | Ablexis, Llc | Myszy knock-in do wytwarzania chimerycznych przeciwciał |
| CN110655573B (zh) * | 2010-02-26 | 2023-07-18 | 生命北极神经科学公司 | 原细纤维结合抗体及其治疗和诊断帕金森氏症、路易体痴呆和其他α-共核蛋白病的应用 |
| PL3248462T3 (pl) | 2010-03-31 | 2024-07-08 | Ablexis, Llc | Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych |
| WO2012045882A2 (en) * | 2010-10-07 | 2012-04-12 | Ac Immune S.A. | Pharmaceutical composition |
| JP6358953B2 (ja) * | 2011-10-07 | 2018-07-18 | エーシー イミューン エス．エー． | タウを認識するホスホ特異的抗体 |
| CA2859665C (en) | 2011-12-20 | 2024-05-21 | Janssen Biotech, Inc. | Anti-phf-tau antibodies and their uses |
| EP2885010B1 (en) | 2012-08-16 | 2020-01-01 | Ipierian, Inc. | Methods of treating a tauopathy |
| JP6284548B2 (ja) * | 2012-12-21 | 2018-02-28 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | ヒト抗タウ抗体 |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| WO2019118906A2 (en) * | 2017-12-14 | 2019-06-20 | University Of Florida Research Foundation | Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein |
| AU2019244481A1 (en) * | 2018-03-28 | 2020-10-01 | Axon Neuroscience Se | Antibody-based methods of detecting and treating Alzheimer's disease |
-
2021
- 2021-12-15 KR KR1020237024245A patent/KR20230157296A/ko active Pending
- 2021-12-15 CN CN202180093407.1A patent/CN117043183A/zh active Pending
- 2021-12-15 US US18/267,711 patent/US20240059766A1/en active Pending
- 2021-12-15 IL IL303638A patent/IL303638A/en unknown
- 2021-12-15 CA CA3205586A patent/CA3205586A1/en active Pending
- 2021-12-15 EP EP21844118.6A patent/EP4263599A1/en active Pending
- 2021-12-15 WO PCT/US2021/063551 patent/WO2022132923A1/en not_active Ceased
- 2021-12-15 JP JP2023536348A patent/JP2023554382A/ja active Pending
- 2021-12-15 MX MX2023007181A patent/MX2023007181A/es unknown
- 2021-12-15 TW TW110147015A patent/TW202239765A/zh unknown
- 2021-12-15 AU AU2021403010A patent/AU2021403010A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL303638A (en) | 2023-08-01 |
| AU2021403010A1 (en) | 2023-07-13 |
| WO2022132923A1 (en) | 2022-06-23 |
| US20240059766A1 (en) | 2024-02-22 |
| JP2023554382A (ja) | 2023-12-27 |
| AU2021403010A9 (en) | 2024-09-26 |
| KR20230157296A (ko) | 2023-11-16 |
| CA3205586A1 (en) | 2022-06-23 |
| TW202239765A (zh) | 2022-10-16 |
| EP4263599A1 (en) | 2023-10-25 |
| CN117043183A (zh) | 2023-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012752A (es) | Compuestos de union a tau. | |
| WO2020176597A9 (en) | N-substituted indoles and other heterocycles for treating brain disorders | |
| PH12020552229A1 (en) | Il-11ra antibodies | |
| MX2023013912A (es) | Metodos para inhibir ras. | |
| EP4442278A3 (en) | Humanized antibodies against c-kit | |
| PH12020552010A1 (en) | Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof | |
| PH12019501929A1 (en) | Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same | |
| PH12022551150A1 (en) | Biparatopic cd73 antibodies | |
| GEAP202114672A (en) | Antibodies specific for hyperphosphorylated tau and methods of use thereof | |
| MX2009009636A (es) | Metodos para tratar enfermedades oftalmicas. | |
| MX2023004869A (es) | Anticuerpos contra sars-cov-2 y usos de los mismos. | |
| MX350355B (es) | Composiciones y metodos para aumentar la masa muscular y la fuerza muscular antagonizando especificamente gdf8 y/o activina a. | |
| TW200635607A (en) | Humanized Aβ antibodies for use in improving cognition | |
| AU2017269839A1 (en) | Methods for treatment of refractory generalized myasthenia gravis | |
| SG142330A1 (en) | Anti-cd38 human antibodies and uses therefor | |
| MX2025003082A (es) | Compuestos de union a tau | |
| BR112022008821A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| PH12022552371A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
| JOP20210166A1 (ar) | علاج الصداع الناتج عن فرط استعمال الأدوية باستخدام أجسام مضادة لـcgrp أو أجسام مضادة لـcgrp-r | |
| PH12020551373A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| MX2023002106A (es) | Anticuerpos fgfr3 y metodos de uso. | |
| MX2021007589A (es) | Anticuerpos anti il-36 y procedimientos de uso de estos. | |
| EP4582446A3 (en) | Methods of treating al amyloidosis | |
| ZA202110285B (en) | Antibodies and methods of use | |
| PH12022550277A1 (en) | Biopharmacuetical compositions and related methods |